Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02136862 · ClinicalTrials.gov registry record
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 165
- Enrollment target
NCT02136862 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 165 participants.
The verdict
NCT02136862 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 165 participants
- Enrollment target
Study Summary
There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients. Patients with a confirmed diagnosis of Alport syndrome who have qualifying GFR will be considered for enrollment. The sequential sampling of subjects' urine and/or blood will allow an assessment of the rate of change of established clinical endpoints, such as GFR and/or the rate of change of other renal biomarkers (proteinuria and β-2 microglobulin) in subjects whose renal function is steadily declining. The identification of surrogate markers that track the decline of renal function and could correlate with time to end-stage renal disease (ESRD) is a key goal of the natural history study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2017-12-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02136862
The ClinicalTrials.gov registry entry for NCT02136862 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02136862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02136862 about?
NCT02136862 is a clinical study titled "ATHENA: Natural History of Disease Study in Alport Syndrome Patients". There is limited published clinical data about the natural history of renal disease in Alport syndrome. The RG012-01 study will collect data to characterize the progression of renal dysfunction in Alport syndrome patients. Patients with a confirmed diagnosis of Alport syndrome who have qualifying G...
What is the current status of trial NCT02136862?
This trial is currently completed. The enrollment target is 165 participants. The study started on 2014-09-04. Estimated completion is 2017-12-18.
Who is sponsoring clinical trial NCT02136862?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.